Cardiac-Specific Overexpression of Peroxisome Proliferator–Activated Receptor-α Causes Insulin Resistance in Heart and Liver
- So-Young Park1,
- You-Ree Cho1,
- Brian N. Finck2,
- Hyo-Jeong Kim1,
- Takamasa Higashimori1,
- Eun-Gyoung Hong1,
- Mi-Kyung Lee1,
- Cheryl Danton1,
- Swati Deshmukh1,
- Gary W. Cline1,
- Julie J. Wu3,
- Anton M. Bennett3,
- Beverly Rothermel4,
- April Kalinowski5,
- Kerry S. Russell5,
- Young-Bum Kim6,
- Daniel P. Kelly2 and
- Jason K. Kim17
- 1Department of Internal Medicine, Section of Endocrinology and Metabolism, Yale University School of Medicine, New Haven, Connecticut
- 2Department of Medicine, Center for Cardiovascular Research, Washington University School of Medicine, St. Louis, Missouri
- 3Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut
- 4Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas
- 5Section of Cardiology, Yale University School of Medicine, New Haven, Connecticut
- 6Division of Endocrinology, Diabetes, and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
- 7Yale Mouse Metabolic Phenotyping Center, Yale University School of Medicine, New Haven, Connecticut
- Address correspondence and reprint requests to Prof. Jason K. Kim, Yale University School of Medicine, Department of Internal Medicine, Section of Endocrinology and Metabolism, The Anlyan Center, S269C, P.O. Box 208020, 300 Cedar St., New Haven, CT 06520-8020. E-mail: jason.k.kim{at}yale.edu
Abstract
Diabetic heart failure may be causally associated with alterations in cardiac energy metabolism and insulin resistance. Mice with heart-specific overexpression of peroxisome proliferator–activated receptor (PPAR)α showed a metabolic and cardiomyopathic phenotype similar to the diabetic heart, and we determined tissue-specific glucose metabolism and insulin action in vivo during hyperinsulinemic-euglycemic clamps in awake myosin heavy chain (MHC)-PPARα mice (12–14 weeks of age). Basal and insulin-stimulated glucose uptake in heart was significantly reduced in the MHC-PPARα mice, and cardiac insulin resistance was mostly attributed to defects in insulin-stimulated activities of insulin receptor substrate (IRS)-1–associated phosphatidylinositol (PI) 3-kinase, Akt, and tyrosine phosphorylation of signal transducer and activator of transcription 3 (STAT3). Interestingly, MHC-PPARα mice developed hepatic insulin resistance associated with defects in insulin-mediated IRS-2–associated PI 3-kinase activity, increased hepatic triglyceride, and circulating interleukin-6 levels. To determine the underlying mechanism, insulin clamps were conducted in 8-week-old MHC-PPARα mice. Insulin-stimulated cardiac glucose uptake was similarly reduced in 8-week-old MHC-PPARα mice without changes in cardiac function and hepatic insulin action compared with the age-matched wild-type littermates. Overall, these findings indicate that increased activity of PPARα, as occurs in the diabetic heart, leads to cardiac insulin resistance associated with defects in insulin signaling and STAT3 activity, subsequently leading to reduced cardiac function. Additionally, age-associated hepatic insulin resistance develops in MHC-PPARα mice that may be due to altered cardiac metabolism, functions, and/or inflammatory cytokines.
Footnotes
-
D.P.K. has received consulting fees from Pfizer Global Research and Development and Sankyo.
2-[14C]DG, 2-deoxy-d-[1-14C]glucose; 2-[14C]DG-6-P, 2-[14C]DG-6-phosphate; GSK, glycogen synthase kinase; HGP, hepatic glucose production; IL, interleukin; IRS, insulin receptor substrate; MAPK, mitogen-activated protein kinase; MHC, myosin heavy chain; PET, positron emission tomography; PI, phosphatidylinositol; PPAR, peroxisome proliferator–activated receptor; STAT3, signal transducer and activator of transcription 3.
-
- Accepted June 16, 2005.
- Received February 21, 2005.
- DIABETES














